Last edition
News about "Dostarlimab MSI-H dMMR rectal cancer"
US FDA Grants Dostarlimab Approval for Rectal Cancer
The US FDA has granted accelerated approval to GSK’s Jemperli (dostarlimab) for adults with stage 2/3 MSI-H or dMMR Locally Advanced Rectal Cancer (LARC).
Dostarlimab MSI-H DMMR Rectal Cancer | 21/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members